Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement
This article was originally published in The Pink Sheet Daily
Executive Summary
What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December but not yet launched.